HRT Without the Fear: Benefits, Risks and Who It's For
Hormone replacement therapy has spent two decades wrapped in fear. Here is what the types are, what the big study found, how thinking has changed, and who should and should not take it.
TL;DR: HRT replaces the oestrogen your body makes less of around menopause, plus progestogen if you still have a womb. It is the most effective treatment for hot flushes and night sweats and protects bones. The scary headlines from 2002 came from a study of mostly older women on tablets. For most women under 60 without a history of breast cancer or blood clots, guidelines say the benefits usually outweigh the risks. It is a personal decision to make with a clinician.
Maybe your mother told you HRT causes cancer. Maybe an aunty in Lagos or Nairobi said she pushed through menopause with nothing but a hand fan and prayer, so you should too. Or maybe a doctor once waved the idea away before you could finish your sentence. For a lot of women, HRT sits somewhere between a rumour and a threat. Meanwhile the hot flushes, broken sleep and low mood carry on. This post is not here to sell you HRT. It is here to put the evidence on the table, so you can decide with your clinician instead of with fear.
What is HRT?
HRT, or hormone replacement therapy, is medicine that tops up the hormones that fall during perimenopause and after menopause, mainly oestrogen. It is used to ease symptoms such as hot flushes, night sweats, vaginal dryness and mood changes. If you are not sure which stage you are in, our guide to perimenopause symptoms is a good place to start.
The types, in plain language
There are two main kinds. Oestrogen-only HRT is for women who have had a hysterectomy. Combined HRT contains oestrogen plus a progestogen, and it is for anyone who still has a womb, because taking both helps protect against womb cancer. Oestrogen on its own can thicken the womb lining, and the progestogen keeps that in check.
How you take it matters too. The NHS lists tablets, skin patches, gels and sprays, and the progestogen part can also come from a hormonal coil (the Mirena), which releases it directly into the womb. Patches, gels and sprays put oestrogen in through the skin, and that route turns out to be important for safety, as you will see below.
Then there is vaginal oestrogen: a low-dose cream, pessary, tablet or ring used inside the vagina for dryness, soreness and urinary symptoms. It works locally, and the NHS notes it does not need a progestogen even if you have a womb. We cover it in depth in our post on vaginal dryness after menopause.
What did the Women's Health Initiative study find?
In 2002, a large US trial called the Women's Health Initiative (WHI) stopped its combined HRT arm early after finding more breast cancer, heart disease, stroke and blood clots in women taking hormones than in those taking a placebo. The headlines went around the world, and HRT use dropped sharply almost overnight.
What got lost was who was in the study. The average age of the women was 63, more than a decade past the typical age of menopause, and they were taking oral tablets. Many were starting hormones long after their symptoms had begun. When researchers followed the WHI participants for longer and looked by age, the picture changed. Women aged 50 to 59 had lower absolute risks and more favourable results than older women, and in the oestrogen-only arm, younger women did better on overall health measures.
That does not mean the risks were invented. It means age, timing, type and route all matter, and the 2002 results were applied to women they did not describe well.
Where the guidance stands now
In the UK, the NHS says that for most women under 60 who are not at high risk of breast cancer or blood clots, the benefits of HRT generally outweigh the risks. NICE's menopause guideline asks clinicians to talk women through the benefits and risks of HRT for their own situation, rather than refusing or pushing it.
In the US, the Menopause Society's 2022 position statement concluded that hormone therapy remains the most effective treatment for hot flushes and for genitourinary symptoms, helps prevent bone loss and fractures, and that women under 60 or within 10 years of menopause tend to get the most benefit with the lowest risk. In November 2025, the US FDA announced it would remove the boxed warnings about heart disease, breast cancer and dementia from HRT labels, while keeping the womb cancer warning for oestrogen-only products. Some experts welcomed this and others felt it went further than the evidence, which is a reminder that individual advice still matters most.
What are the risks of HRT?
The main risks are a small rise in breast cancer with combined HRT and a higher chance of blood clots with tablets. Both depend on the type, the route and your own health, and both are lower than many women fear.
Here are the numbers the NHS gives. With combined HRT, there are around 5 extra cases of breast cancer for every 1,000 women who take it for 5 years, and the risk falls again after stopping. Oestrogen-only HRT carries little or no increase. Tablets slightly raise the risk of blood clots and stroke, but patches, gels and sprays do not raise blood clot risk, which is why a clinician may steer you towards the skin if you have extra risk factors. On the benefit side, HRT helps protect your bones, which matters because bone loss speeds up after menopause. Our post on bone health and osteoporosis explains why.
Who should not take HRT?
HRT is not suitable for everyone. The NHS says it may not be right if you have a history of breast, ovarian or womb cancer, a history of blood clots, untreated high blood pressure, or liver disease, or if you are pregnant. Some of these are not a flat no. A history of clots may mean a patch instead of a tablet, and high blood pressure usually needs to be brought under control first.
Unexplained vaginal bleeding after menopause should always be checked by a doctor before starting any hormones, and at any time it happens. If HRT is not an option for you, there are non-hormonal treatments and lifestyle approaches, and NICE covers these too.
Access and cost if you live in Africa
Here is the part most HRT articles skip. In much of Africa, getting HRT is hard. The WHO notes that many health systems lack policies, trained providers and funding for menopause care, especially where other health needs compete for resources. A survey of women attending a gynaecology clinic in Enugu, Nigeria, found only 38.9% had any knowledge of HRT, and none were using it, despite having menopausal symptoms.
In practice that often means paying out of pocket, a limited choice of brands at the pharmacy, and fewer clinicians comfortable prescribing it. If you are in Nigeria, Kenya, Ghana or South Africa, ask a gynaecologist or a hospital menopause clinic rather than buying hormones informally, and ask which forms are stocked locally and what they cost each month. In the UK, HRT prescriptions can be covered by an HRT prescription prepayment certificate, which cuts the cost to one yearly fee. If you are in the diaspora, that is worth knowing about.
How to have the conversation
Go in with specifics. Which symptoms, how often, how long, and how they affect your work, sleep and relationships. Bring your family history, especially breast cancer, clots and heart disease. Ask about types and routes, and what follow-up looks like. If you have felt dismissed before, our guide on how to talk to your gynaecologist has scripts that help.
This is where Asele can help, quietly. Symptom logging and cycle tracking show you how often the hot flushes come and how your sleep and mood shift, so you have a record instead of a guess. The Asele Health Brief turns that into a pre-visit summary you can take to your doctor. And Amara can talk through your questions beforehand in Yoruba, Hausa, Igbo, Swahili, French or English. You can find us at Asele.
This post is education, not medical advice. Decisions about HRT should be made with a clinician who knows your history.
References
- NHS. Types of hormone replacement therapy (HRT). nhs.uk
- NHS. Benefits and risks of hormone replacement therapy (HRT). nhs.uk
- NHS. About hormone replacement therapy (HRT). nhs.uk
- NICE. Menopause: identification and management (NG23). nice.org.uk
- The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. doi.org
- Manson JE. The Women's Health Initiative: the latest findings from long-term follow-up. Women's Health. 2014. doi.org
- US Food and Drug Administration. HHS advances women's health, removes misleading FDA warnings on hormone replacement therapy. November 2025. fda.gov
- World Health Organization. Menopause fact sheet. who.int
- A survey of women's knowledge and perception of hormone replacement therapy (HRT) in Enugu, South East Nigeria. Niger J Med. 2013;22(4):332-5. pubmed.ncbi.nlm.nih.gov
← Back to The Journal
